Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
life sciences & biomedicine (16) 16
science & technology (16) 16
adult (15) 15
female (15) 15
male (15) 15
psychiatry (13) 13
benzodiazepines - therapeutic use (11) 11
middle aged (11) 11
antipsychotic agents - therapeutic use (10) 10
treatment outcome (10) 10
olanzapine (9) 9
double-blind method (8) 8
drug therapy (8) 8
psychopharmacology (7) 7
schizophrenia (7) 7
adolescent (6) 6
biological and medical sciences (6) 6
clinical trials (6) 6
medical sciences (6) 6
neuropharmacology (6) 6
pharmacology. drug treatments (6) 6
psychology. psychoanalysis. psychiatry (6) 6
adult and adolescent clinical studies (5) 5
benzodiazepines - adverse effects (5) 5
pharmacology & pharmacy (5) 5
psycholeptics: tranquillizer, neuroleptic (5) 5
psychopathology. psychiatry (5) 5
schizophrenia - drug therapy (5) 5
severity of illness index (5) 5
aged (4) 4
antipsychotic agents - adverse effects (4) 4
drug therapy, combination (4) 4
general & internal medicine (4) 4
medicine, general & internal (4) 4
patients (4) 4
psoriasis (4) 4
psoriasis - drug therapy (4) 4
antibodies, monoclonal, humanized - adverse effects (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
depression (3) 3
depressive disorder, major - drug therapy (3) 3
dose-response relationship, drug (3) 3
drug resistance (3) 3
fluoxetine - adverse effects (3) 3
fluoxetine - therapeutic use (3) 3
monoclonal antibodies (3) 3
mood disorders (3) 3
neurosciences (3) 3
neurosciences & neurology (3) 3
psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (3) 3
research (3) 3
time factors (3) 3
weight gain - drug effects (3) 3
abridged index medicus (2) 2
antibodies, monoclonal, humanized - administration & dosage (2) 2
antipsychotic drugs (2) 2
aripiprazole (2) 2
blood glucose - drug effects (2) 2
care and treatment (2) 2
clinical neurology (2) 2
clinical trials as topic (2) 2
comparative analysis (2) 2
cytokines (2) 2
databases, factual (2) 2
dermatology (2) 2
diagnostic and statistical manual of mental disorders (2) 2
drug administration schedule (2) 2
etanercept (2) 2
follow-up studies (2) 2
health aspects (2) 2
injections, subcutaneous (2) 2
japan (2) 2
medication adherence - psychology (2) 2
medication adherence - statistics & numerical data (2) 2
medicine (2) 2
original (2) 2
original article (2) 2
original articles (2) 2
patient compliance (2) 2
pharmacokinetics (2) 2
piperazines - therapeutic use (2) 2
psychiatric status rating scales (2) 2
psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer (2) 2
psychology (2) 2
psychology, clinical (2) 2
psychoses (2) 2
psychotropic drugs (2) 2
quinolones - therapeutic use (2) 2
risk factors (2) 2
schizophrenic psychology (2) 2
social sciences (2) 2
triglycerides (2) 2
weight (2) 2
ademetionine, therapeutic use (1) 1
adult; antibodies, monoclonal, humanized; candidiasis; female; humans; inflammatory bowel diseases; intention to treat analysis; male; middle aged; neutropenia; psoriasis; severity of illness index; medicine (1) 1
affect (1) 1
affective disorders (1) 1
age differences (1) 1
age factors (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
by Griffiths, Christopher E M, Prof and Reich, Kristian, Prof and Lebwohl, Mark, Prof and van de Kerkhof, Peter, Prof and Paul, Carle, Prof and Menter, Alan, MD and Cameron, Gregory S, PhD and Erickson, Janelle, PhD and Zhang, Lu, MS and Secrest, Roberta J, PhD and Ball, Susan, PhD and Braun, Daniel K, MD and Osuntokun, Olawale O, MD and Heffernan, Michael P, MD and Nickoloff, Brian J, MD and Papp, Kim, MD and UNCOVER-3 investigators and UNCOVER-2 and UNCOVER-2 & UNCOVER-3 and UNCOVER-2 and UNCOVER-3 investigators
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 9993, pp. 541 - 551
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Psoriasis - drug therapy | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Immunoglobulin G - therapeutic use | Male | Treatment Outcome | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Adult | Female | Chronic Disease | Monoclonal antibodies | Product development | Comparative analysis | Psoriasis | Cytokines | Clinical trials | TNF inhibitors | Tumor necrosis factor-TNF | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (UNCOVER‐J)
by Saeki, Hidehisa and Nakagawa, Hidemi and Nakajo, Ko and Ishii, Taeko and Morisaki, Yoji and Aoki, Takehiro and Cameron, Gregory S and Osuntokun, Olawale O and Akasaka, Toshihide and Asano, Yoshihide and Etoh, Takafumi and Fujita, Yasuyuki and Hashimoto, Takashi and Higashiyama, Mari and Igarashi, Atsuyuki and Ihn, Hironobu and Iwatsuki, Keiji and Kabashima, Kenji and Kawada, Akira and Kawashima, Makoto and Nakamura, Koichiro and Okubo, Yukari and Okuyama, Ryuhei and Ozawa, Akira and Sayama, Koji and Seishima, Mariko and Shiohara, Tetsuo and Takahara, Masakazu and Takahashi, Hidetoshi and Takehara, Kazuhiko and Tanese, Keiji and Tani, Mamori and Umezawa, Yoshinori and Watanabe, Hideaki and Yamanaka, Keiichi and Japanese Ixekizumab Study Grp and Japanese Ixekizumab Study Group and the Japanese Ixekizumab Study Group
Journal of dermatology, ISSN 0385-2407, 04/2017, Volume 44, Issue 4, pp. 355 - 362
ixekizumab | plaque psoriasis | erythrodermic psoriasis | generalized pustular psoriasis | Japan | Life Sciences & Biomedicine | Dermatology | Science & Technology | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Nails | Dermatologic Agents - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Dermatologic Agents - therapeutic use | Dermatologic Agents - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Interleukin-17 - antagonists & inhibitors | Long Term Adverse Effects - chemically induced | Scalp | Arthritis, Psoriatic - drug therapy | Injections, Subcutaneous | Adult | Female | Long Term Adverse Effects - epidemiology | Monoclonal antibodies | Skin diseases | Care and treatment | Arthritis | Prescription drugs | Psoriasis | Pharmaceutical industry | Urticaria | Seborrheic dermatitis | Rhinopharyngitis | FDA approval | Dermatitis | Patients | Eczema | Remission | Plaques | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
by Gordon, Kenneth B and Blauvelt, Andrew and Papp, Kim A and Langley, Richard G and Luger, Thomas and Ohtsuki, Mamitaro and Reich, Kristian and Amato, David and Ball, Susan G and Braun, Daniel K and Cameron, Gregory S and Erickson, Janelle and Konrad, Robert J and Muram, Talia M and Nickoloff, Brian J and Osuntokun, Olawale O and Secrest, Roberta J and Zhao, Fangyi and Mallbris, Lotus and Leonardi, Craig L and UNCOVER-3 Study Group and UNCOVER-1 Study Group and UNCOVER-2 Study Group
The New England journal of medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 4, pp. 345 - 356
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Humans | Middle Aged | Male | Candidiasis - etiology | Intention to Treat Analysis | Adult | Female | Inflammatory Bowel Diseases - chemically induced | Neutropenia - chemically induced | Treatment outcome | Care and treatment | Psoriasis | Analysis | Risk factors | Inflammatory bowel diseases | Etanercept | Cytokines | Intestine | Clinical trials | Monoclonal antibodies | Skin | Drug therapy | Patients | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Therapeutic options for treatment-resistant depression
by Shelton, Richard C and Osuntokun, Olawale and Heinloth, Alexandra N and Corya, Sara A
CNS drugs, ISSN 1172-7047, 2010, Volume 24, Issue 2, pp. 131 - 161
Pharmacology & Pharmacy | Clinical Neurology | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Humans | Psychotherapy | Psychotropic Drugs - administration & dosage | Treatment Outcome | Clinical Trials as Topic | Vagus Nerve Stimulation | Transcranial Magnetic Stimulation | Depression - drug therapy | Deep Brain Stimulation | Antidepressive Agents - administration & dosage | Electroconvulsive Therapy | Depression - therapy | Drug Therapy, Combination | Drug Resistance
Journal Article
Details down arrow
5. Full Text Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
by Brunner, Elizabeth and Tohen, Mauricio and Osuntokun, Olawale and Landry, John and Thase, Michael E
Neuropsychopharmacology (New York, N.Y.), ISSN 0893-133X, 10/2014, Volume 39, Issue 11, pp. 2549 - 2559
Pharmacology & Pharmacy | Neurosciences | Neurosciences & Neurology | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Hospitalization | Depressive Disorder, Treatment-Resistant - drug therapy | Secondary Prevention - methods | Suicide | Antidepressive Agents - therapeutic use | Psychiatric Status Rating Scales | Time Factors | Adult | Female | Weight Gain - drug effects | Benzodiazepines - adverse effects | Antidepressive Agents - adverse effects | Fluoxetine - therapeutic use | Benzodiazepines - therapeutic use | Drug Combinations | Fluoxetine - adverse effects | Depressive Disorder, Major - drug therapy | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia
by Liu-Seifert, Hong and Osuntokun, Olawale O and Feldman, Peter D
Comprehensive psychiatry, ISSN 0010-440X, 2012, Volume 53, Issue 1, pp. 107 - 115
Psychiatry | Life Sciences & Biomedicine | Science & Technology | Psycholeptics: tranquillizer, neuroleptic | Psychology. Psychoanalysis. Psychiatry | Psychoses | Adult and adolescent clinical studies | Psychopharmacology | Pharmacology. Drug treatments | Psychopathology. Psychiatry | Schizophrenia | Biological and medical sciences | Medical sciences | Neuropharmacology | Medication Adherence - psychology | Humans | Middle Aged | Male | Treatment Outcome | Schizophrenic Psychology | Antipsychotic Agents - therapeutic use | Adolescent | Adult | Female | Aged | Quality of Life - psychology | Schizophrenia - drug therapy | Benzodiazepines - therapeutic use | Olanzapine | Drug therapy | Patient compliance | Studies | Clinical trials | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia
by Kinon, Bruce J and Zhang, Lu and Millen, Brian A and Osuntokun, Olawale O and Williams, Judy E and Kollack-Walker, Sara and Jackson, Kimberley and Kryzhanovskaya, Ludmila and Jarkova, Natalia and HBBI Study Grp and HBBI Study Group
Journal of clinical psychopharmacology, ISSN 0271-0749, 06/2011, Volume 31, Issue 3, pp. 349 - 355
olanzapine | metabotropic glutamate receptor 2 (mGluR2) | schizophrenia | metabotropic glutamate receptor 3 (mGluR3) | glutamate | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Psychiatry | Science & Technology | Medication Adherence - statistics & numerical data | Diagnostic and Statistical Manual of Mental Disorders | Double-Blind Method | Humans | Middle Aged | Male | Amino Acids - administration & dosage | Amino Acids - adverse effects | Amino Acids - therapeutic use | Dose-Response Relationship, Drug | Inpatients | Psychiatric Status Rating Scales | Antipsychotic Agents - therapeutic use | Adolescent | Adult | Female | Aged | Prodrugs - therapeutic use | Schizophrenia - drug therapy | Receptors, Metabotropic Glutamate - agonists | Benzodiazepines - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights